| Literature DB >> 28408606 |
Sanja Stevanović1, Anna Pasetto2, Sarah R Helman3, Jared J Gartner2, Todd D Prickett2, Bryan Howie4, Harlan S Robins4,5, Paul F Robbins2, Christopher A Klebanoff6,7, Steven A Rosenberg2, Christian S Hinrichs1.
Abstract
Immunotherapy has clinical activity in certain virally associated cancers. However, the tumor antigens targeted in successful treatments remain poorly defined. We used a personalized immunogenomic approach to elucidate the global landscape of antitumor T cell responses in complete regression of human papillomavirus-associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy. Remarkably, immunodominant T cell reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than canonical viral antigens. T cells targeting viral tumor antigens did not display preferential in vivo expansion. Both viral and nonviral tumor antigen-specific T cells resided predominantly in the programmed cell death 1 (PD-1)-expressing T cell compartment, which suggests that PD-1 blockade may unleash diverse antitumor T cell reactivities. These findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated cancers.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28408606 PMCID: PMC6295311 DOI: 10.1126/science.aak9510
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728